Zobrazeno 1 - 10
of 62
pro vyhledávání: '"H. J. Keizer"'
Autor:
Yvonne Vergouwe, Laurence Collette, Sally P. Stenning, H. J. Keizer, J T Roberts, Ewout W. Steyerberg, R. de Wit, J. D. F. Habbema
Publikováno v:
British Journal of Cancer
British Journal of Cancer, 88, 843-847. Nature Publishing Group
British Journal of Cancer, 88, 843-847. Nature Publishing Group
We assessed the external validity of a prediction rule for nonseminomatous testicular cancer patients. The rule was developed to predict the probability of retroperitoneal metastases being benign (only necrosis/fibrosis) after chemotherapy treatment.
Publikováno v:
Annals of Oncology. 12:1353-1357
Peritonitis carcinomatosa, indicating the presence of malignant cells in the peritoneal cavity, is a well-known complication of malignant disease. As a result, so-called malignant ascites develops. Malignant ascites is a debilitating condition for wh
Autor:
Sjoerd Rodenhuis, Ron A. A. Mathot, H. J. Keizer, Jos H. Beijnen, Jan Ouwerkerk, Jan H.M. Schellens, T. Kerbusch
Publikováno v:
European Journal of Clinical Pharmacology. 57:467-477
Objective: The population pharmacokinetics and pharmacodynamics of the cytostatic agent ifosfamide and its main metabolites 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide were assessed in patients with soft tissue sarcoma. Methods: Twenty p
Autor:
H. J. Keizer, Thomas Kerbusch, J. Ouwerkerk, A. D. R. Huitema, Jan H.M. Schellens, Ron A. A. Mathot, Jos H. Beijnen
Publikováno v:
British Journal of Clinical Pharmacology. 49:555-561
Aims This study investigated the population pharmacokinetics of ifosfamide in 15 patients treated for soft tissue sarcoma with 9 or 12 g m−2 ifosfamide by means of a 72 h continuous i.v. infusion. Methods A model was developed using nonlinear mixed
Publikováno v:
International Journal of Cancer. 83:856-859
Patients with metastatic non-seminomatous testicular cancer can be cured by cisplatin-based chemotherapy. After chemotherapy, surgical resection is a generally accepted treatment to remove remnants of the initial metastases since residual tumor may s
Publikováno v:
Anti-Cancer Drugs. 9:381-385
A multicenter, open-label, compassionate-use trial studied the antiemetic efficacy and tolerability of granisetron in patients who had failed other antiemetic therapies in previous cycles of cytostatic chemotherapy. The antiemetics that had been used
Autor:
H. J. Keizer, A. Marinelli, U. R. Tjaden, J.H. van Bockel, L. M. de Brauw, C.J.H. van de Velde, H. Beerman
Publikováno v:
Japanese Journal of Clinical Oncology. 26:341-350
We evaluated the technical feasibility of isolated liver perfusion (ILP) in the treatment of patients with colorectal cancer metastases confined to the liver, and investigated whether ILP allows exposure of the tumor to high concentrations of mitomyc
Autor:
Jonathan E. Messemer, H. J. Keizer, Guy C. Toner, John P. Donohue, H. Schraffordt Koops, Sophie D. Fosså, Ewout W. Steyerberg, Dt Sleijfer, P.F.A. Mulders, K. Ney
Publikováno v:
Journal of Clinical Oncology. 13:1177-1187
PURPOSE To develop a statistical model that predicts the histology (necrosis, mature teratoma, or cancer) after chemotherapy for metastatic nonseminomatous germ cell tumor (NSGCT). PATIENTS AND METHODS An international data set was collected comprisi
Publikováno v:
Journal of cancer research and clinical oncology
The thymidine analogue (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdUrd), which is an antiviral agent effective against herpes simplex virus type 1 and varicella zoster virus, has also proved to be a potent inhibitor of dihydrouracil dehydrogenase, the m
Autor:
P. Czygan, D. Zylberait, H. Illiger, Jm. Haefliger, P. Harper, M. Harjung, L. Cals, R. Plagne, D. Piguet, M. Namer, A. Cattan, H. J. Keizer, Michel Clavel, H. J. König, P. Kerbrat, K. Bremer, A. Nobel, F. Oberling, J. Bauer, B. Hunter, A. Rivière, K. Giger, Stan B. Kaye, V. Diehl, M. Soukop, P. Moncuquet, A. Reichle, M. Aapro, David P. Dearnaley, C. H. N. Veenhof, J. W. R. Nortier
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 119:555-559
The antiemetic efficacy and safety of granisetron (40 μg/kg), a selective and potent 5-hydroxytryptamine (serotonin) antagonist, was compared with that of metoclopramide (7 mg/kg) plus dexamethasone (12 mg) in patients receiving fractionated chemoth